Detalhe da pesquisa
1.
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Cancer Immunol Immunother
; 72(1): 183-191, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779095
2.
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Gynecol Oncol
; 157(1): 214-221, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31959492
3.
Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation.
Int J Gynecol Cancer
; 23(9): 1635-41, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24172099
4.
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission.
Cancers (Basel)
; 15(5)2023 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900251
5.
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.
Cancer
; 118(9): 2403-10, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21935916
6.
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.
J Immunother Cancer
; 9(8)2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433633
7.
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.
Cancers (Basel)
; 8(4)2016 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27110823